Looming weight-loss drug boom must not replace preventive action on rising obesity
India’s March 20 patent expiry on semaglutide could prove a watershed in the global fight against obesity. With the molecule behind GLP-1 drugs like Wegovy and Ozempic now open to generic competition, Indian pharmaceutical companies…
